Vor Biopharma

Robert Ang, President and CEO

April 21 | 2:45pm | Gaudi 3 Ballroom

Cambridge, MA

(NASDAQ: VOR)

In-Person Presentation

Vor Biopharma is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. Our vision is to cure blood cancers through cell and genome engineering.

www.vorbio.com



By using this website you agree to accept our Privacy Policy and Terms & Conditions